Clinical Trial Update: Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated the combination of rituximab and interleukin-2 in patients with lymphoma; the update provides status on this study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Rituximab (rituximab)

Snippet

Sponsor: University of Rochester | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED